LGI-1抗体相关的面臂肌张力障碍的研究进展  

Advances in Leucine-rich Glioma-inactivated 1 Antibody-associated Faciobrachial Dystonic Seizures

作　　者：杨欣睿 陈阳美[1] YANG Xin-rui;CHEN Yang-mei(Department of Neurology,the Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学附属第二医院神经内科,重庆400010

出　　处：《中国临床神经科学》2023年第2期184-190,共7页Chinese Journal of Clinical Neurosciences

摘　　要：与富亮氨酸胶质瘤灭活蛋白1(LGI-1)抗体相关的面臂肌张力障碍(FBDS)是抗LGI-1脑炎的特征性表现,可早于其他症状出现,识别这种独特的发作类型为早期治疗提供了机会。但对FBDS临床特征的认识不足,常导致诊断的延迟或误诊。FBDS的致病机制尚不清楚,近年有研究通过神经影像学、电生理等方法探讨FBDS的发病机制。此外,LGI-1抗体相关FBDS的治疗受到越来越多的关注,包括抗癫癎治疗和免疫治疗。目前,对LGI-1抗体相关的FBDS发病机制、临床特征、辅助检查及治疗方案的选择,尚缺乏系统性描述。文中就LGI-1抗体相关FBDS的最新研究进展做总结。Faciobrachial dystonic seizures(FBDS)associated with leucine-rich glioma-inactivated protein 1(LGI-1)antibodies is a characteristic manifestation of anti LGI-1 encephalitis,which may precede other symptoms,and it can be used to identify this distinctive type of attack for an opportunity for early treatment.However,due to the neglect of the clinical characteristics of FBDS,the diagnosis is often delayed or misdiagnosed.The origin of FBDS is still unclear.In recent years,some studies have elucidated the mechanism of FBDS through neuroimaging and electrophysiology.In addition,many researchers have focused on the treatment of FBDS associated with LGI-1 antibody,including antiepileptic therapy and immunotherapy.There is still a lack of a systematic description of the clinical characteristics,mechanism,auxiliary examination and treatment options of LGI-1 antibody-related FBDS.The recent progress on FBDS was overviewed.

关 键 词：面臂肌张力障碍 LGI-1抗体 机制 治疗 

分 类 号：R742[医药卫生—神经病学与精神病学]